Evidence map›Paper›PMID 42856301›Full record

ArticlebioRxiv : the preprint server for biology2026

Antibody-recruiting molecules based on mimotope fusion peptides and a dimeric antibiotic.

Franz G Zingl, Meilee L Mekalanos, Deborah R Leitner, Stephen R Walsh, Matthew K Waldor, John J Mekalanos

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Franz G ZinglDepartment of Microbiology, Harvard Medical School, Boston, MA, USA.ORCID 0000-0003-0874-4234
Meilee L MekalanosNewton North High School, Newton, MA, USA.
Deborah R LeitnerDepartment of Microbiology, Harvard Medical School, Boston, MA, USA.ORCID 0000-0002-2314-7676
Stephen R WalshDivision of Infectious Diseases, Brigham & Women's Hospital, Boston, MA, USA.ORCID 0000-0002-0817-9370
Matthew K WaldorDepartment of Microbiology, Harvard Medical School, Boston, MA, USA.ORCID 0000-0003-1843-7000
John J MekalanosDepartment of Microbiology, Harvard Medical School, Boston, MA, USA.ORCID 0000-0003-2792-9293

Funding

Genetic analysis of toxinogenesis of Vibrio choleraeR37AI018045 · NIAID · HARVARD UNIVERSITY (MEDICAL SCHOOL) · PI John Joseph Mekalanos · 1989 to 2026
$12.8M
Genetic Analysis of Toxinogenesis in Vibrio CholeraeR01AI018045 · NIAID · HARVARD MEDICAL SCHOOL · PI MEKALANOS, JOHN JOSEPH · 2009 to 2018
$6.7M
NIAID NIH HHS R01 AI018045NIAID NIH HHS R37 AI018045
6 · The paper itself

Abstract

New therapeutic approaches are needed to treat infections due to multidrug resistant (MDR) Gram-negative bacteria. The use of antibody-recruiting molecules (ARMs) is a promising approach to address the MDR problem given their potential to engage both the adaptive and innate immune systems to treat bacterial infections. Here we present two new strategies to create ARMs. First, we show that a 9-mer antimicrobial peptide (K6) can be fused to a 11-mer mimotope peptide recognized by antibodies targeting the

Identifiers

PMID42856301
PMCPMC13648653

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.